Clinical Trials | January 04, 2026
FDA nod to first new motion sickness drug in 40 years
The approval is supported by data from three pivotal clinical trials
The approval is supported by data from three pivotal clinical trials
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
